Study site
St Louis, Missouri 63141
3 studies enrolling now · 11 studies all time
What they study most
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH), Acute Major Bleeding, Blood Coagulation Disorders, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, HAE With Normal C1 Esterase Inhibitor, Hereditary Angioedema, Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
Studies at this site
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency — Recruiting now
- Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE — Recruiting now
- Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema — Enrolling by invitation
- Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE — Running, not enrolling
- Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema — Completed
- Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema — Completed
- Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II — Completed
- A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650 — Completed
- Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia — Completed
- Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy — Completed
- Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy — Completed